指南与共识类风湿关节炎脊柱关节炎

EULAR-OMERACT滑膜炎评分系统十年验证:适用于常规诊疗与临床试验

EULAR-OMERACT consensus-based scoring system for synovitis 10 years later: a validated tool for routine care and clinical trials.
指南 / 共识 · RMD Open · 2026-04-01

该文总结EULAR与OMERACT合作开发的共识性超声滑膜炎评分系统近十年验证结果:该系统具内容效度、区分效度、结构效度与标准效度,观察者间与观察者内信度中至优,24关节评估约需20分钟,并满足OMERACT 2.1工具选择标准。

要点

  • EULAR-OMERACT评分系统对治疗中变化敏感,可区分活性治疗与安慰剂。
  • 该系统对bDMARD停药及减量期间复发具预测效度,且与组织学炎症相关。
  • 24关节评估约20分钟完成,可行性良好并满足OMERACT 2.1筛选标准。

核心结论

  • EULAR-OMERACT共识性超声滑膜炎评分系统是经过验证的评分系统,满足OMERACT 2.1工具选择标准。

研究设计与样本

  • 由欧洲抗风湿病联盟(EULAR)与国际风湿病结局测量组织(OMERACT)合作开发共识性评分系统,并在开发后近十年内完成验证。

主要发现

  • 该系统具表面效度与内容效度,可显示构成滑膜炎复合体的全部成分。
  • 该系统对治疗中变化敏感,可在临床试验中区分活性治疗与安慰剂,观察者间与观察者内信度中至优。
  • 超声总和评分与疾病活动度评分28(DAS28)及关节评估呈平行改善,提示结构效度。
  • 该系统对生物改善病情抗风湿药(bDMARD)停药及减量期间复发具预测效度,并与组织学炎症相关。
  • 24关节评估可在20分钟内完成,提示可行性良好。

关键数值与推荐

  • 原文未报告具体数值阈值、剂量或统计量。

临床怎么用

  • 可将EULAR-OMERACT评分系统用于关节炎患者常规诊疗中滑膜炎的评估与监测。
  • 该评分系统可用于临床试验中滑膜炎的标准化评估,并作为bDMARD停药或减量决策的参考工具。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Assessing the presence and degree of synovitis is the cornerstone of managing patients with arthritis. Ultrasound has been shown to be a valuable tool for this in routine care, and several scoring systems have been developed over time. Although there is an overall good validity across several different semi-quantitative scoring systems, they lack reliability when applied in the same patient cohort, emphasising the need for a consensus-based scoring system. A European Alliance of Associations for Rheumatology (EULAR) and Outcome Measures in Rheumatology (OMERACT) collaboration developed, almost 10 years ago, the consensus-based EULAR-OMERACT scoring system, which has subsequently been validated. It has face and content validity as it makes sense and allows to visualise all components constituting the synovitis complex. It has discriminant validity as it is sensitive to change during treatment, can discriminate between active treatment and placebo in clinical trials and has a moderate-to-excellent inter-observer and intra-observer reliability. It has construct validity by showing a parallel improvement in ultrasound sum scores and Disease Activity Score 28 and joint assessment, respectively. It has criterion validity with a predictive validity for biological disease-modifying antirheumatic drug (bDMARD) discontinuation and for flares while tapering bDMARDs. In addition, a correlation between the scoring system and histological inflammation was established. Finally, the EULAR-OMERACT scoring system is feasible, as a 24-joint assessment can be performed in 20 min. In conclusion, the EULAR-OMERACT scoring system is a valid scoring system that also fulfils the OMERACT 2.1 filter for instrument selection.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Terslev L, D'Agostino MA. EULAR-OMERACT consensus-based scoring system for synovitis 10 years later: a validated tool for routine care and clinical trials. RMD Open. 2026. PMID: 41922080. doi:10.1136/rmdopen-2025-006650

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。